Functional Pathway Analysis Using SCNP of FLT3 Receptor Pathway Deregulation in AML Provides Prognostic Information Independent from Mutational Status

• Alessandra Cesano ,

  * E-mail: Alessandra.Cesano@Nodality.com

  Affiliation Nodality, Inc., South San Francisco, California, United States of America

  ⨯
• Santosh Putta,

  Affiliation Nodality, Inc., South San Francisco, California, United States of America

  ⨯
• David B. Rosen,

  Affiliation Nodality, Inc., South San Francisco, California, United States of America

  ⨯
• Aileen C. Cohen,

  Affiliation Nodality, Inc., South San Francisco, California, United States of America

  ⨯
• Urte Gayko,

  Affiliation Nodality, Inc., South San Francisco, California, United States of America

  ⨯
• Kavita Mathi,

  Affiliation Nodality, Inc., South San Francisco, California, United States of America

  ⨯
• John Woronicz,

  Affiliation Nodality, Inc., South San Francisco, California, United States of America

  ⨯
• Rachael E. Hawtin,

  Affiliation Nodality, Inc., South San Francisco, California, United States of America

  ⨯
• Larry Cripe,

  Affiliations Eastern Cooperative Oncology Group (ECOG), Boston, Massachusetts, United States of America, Indiana University Simon Cancer Center, Indianapolis, Indiana, United States of America

  ⨯
• Zhuoxin Sun,

  Affiliations Eastern Cooperative Oncology Group (ECOG), Boston, Massachusetts, United States of America, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America

  ⨯
• Martin S. Tallman,

  Affiliations Eastern Cooperative Oncology Group (ECOG), Boston, Massachusetts, United States of America, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

  ⨯
• Elisabeth Paietta

  Affiliations Eastern Cooperative Oncology Group (ECOG), Boston, Massachusetts, United States of America, Montefiore Medical Center North Division, Bronx, New York, United States of America

  ⨯